It has been reported that the application of neoadjuvant administration of PD-1 antagonist combined with gemcitabine improved the viability of NK cells and T cells and inhibited the local recurrence of pancreatic cancer. This evidence concerns the gene PDCD1 and pancreatic neoplasm.